The Use of Exogenous Lung Surfactant (Poractant Alfa) in Acute Respiratory Failure by Drowning
| Autor: | Ottorino Perrone, Patrizia Casella, Francesco Givigliano, Annamaria Scozzafava, Carlo Pietro Voci, Mario Pezzi, Mario Verre, Pietro Maglio, Anna Maria Giglio |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
ARDS
Lung Inhalation business.industry RC86-88.9 030208 emergency & critical care medicine Medical emergencies. Critical care. Intensive care. First aid Lung injury Critical Care and Intensive Care Medicine medicine.disease Intensive care unit law.invention 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Pulmonary surfactant law 030225 pediatrics Anesthesia Medicine Poractant alfa Acute respiratory failure Case Series business medicine.drug |
| Zdroj: | Case Reports in Critical Care, Vol 2020 (2020) Case Reports in Critical Care |
| ISSN: | 2090-6439 2090-6420 |
| Popis: | Drowning is an acute respiratory failure as a result from immersion or submersion of the airways in a liquid medium (predominantly water). Inhalation of water causes severe lung damage due to the destruction of pulmonary surfactant, resulting in decreased lung elasticity, alveolar collapse, alteration of ventilation-perfusion ratio, intrapulmonary blood shunting, hypoxia, acute lung injury, and Acute Respiratory Distress Syndrome (ARDS). Poractant alfa (Curosurf®), a natural surfactant effective in the treatment of newborn respiratory distress, has been used in various forms of ARDS, but in drowning syndromes, experience is still poor. We describe a series of nine clinical cases of drowning, six adults and three children, treated in our Intensive Care Unit (ICU) with endobronchial administration of poractant alfa. After 24 and 48 hours of administration in all cases, there was an improvement in arterial blood gas analysis (ABG) parameters and imaging. All patients were discharged without clinical consequences. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text